Vectura Group Share Price (VEC)

142.35 +22.65 (+18.92%) delayed: 6:00AM BST
Bid price 119.70 Open price 0.00
Ask price 165.00 Prev close 119.70
High price 0.00 Spread 27.45%
Low price 0.00 Volume 0

Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.

Vectura Group Share Price Chart

Advanced Charts >>

Register now for FREE Vectura Group share price charts

Vectura Group Share Price Information

Name Vectura Group Epic VEC
Sector Pharmaceuticals & Biotechnology ISIN GB00B01D1K48
Activites Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. Index FTSE 250

Vectura Group Key Numbers

Latest Share Price (p) 142.35 Net Gearing (%) 9.01
Market Capitalisation (£m) 819.08 Gross Gearing (%) 19.94
Shares in issue (m) 678.61 Debt Ratio 12.69
P/E Ratio -22.77 Debt-to-Equity Ratio 0.58
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.25
Dividend Yield (%) 0.00 Price to book value 1.21
Dividend cover (x) 0.00 ROCE (%) -5.17
Earning per share (p) -5.30 EPS Growth (%) -541.67
52 week high / low 172.00 / 119.60 DPS Growth (%) n/a

Vectura Group Director Deals

Dec.Date Type Director Pos No. of Shares
08/05/2017 BUY Andrew Derodra FD 105
07/04/2017 BUY Andrew Derodra FD 99
09/03/2017 BUY Andrew Derodra FD 101
09/02/2017 BUY Andrew Derodra FD 111
03/10/2016 BUY Susan Foden NED 6,500

More Vectura Group Director Deals >>

Vectura Group Company News

07:18 22/05/2017

Vectura to present VR942 positive Phase I data

Vectura Group and co-development partner UCB will present the positive outcomes of the Phase I clinical study (VR942-1-001) for their innovative inhaled biologic VR942 (UCB4144) today. This followed the group's announcement in June 2016 that the study met its primary objective of evaluating the...

07:00 22/05/2017

VR942 Positive Phase I data to be presented at ATS

RNS Number : 7405F Vectura Group plc 22 May 2017         Vectura Group plc     Positive outcomes of the Phase I clinical study on VR942 presented today at the American Thoracic Society 113th annual conference Chippenham, UK - 22 May 2017:...

07:02 22/05/2017

FLASH: Vectura to present VR942 positive Phase I data

Story provided by

More Vectura Group Company News >>

Register now for FREE Vectura Group company news

Vectura Group Share Price Discussions

8 months ago


Powered by IST's

Register now for FREE Vectura Group share price discussions